Todas las investigaciones
AutorizadoConfirmatorio terapéutico (Fase III)Intervencionista

A Phase 3, Randomized, Double-Blind, 48-Week Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of DYNE-101 Administered to Participants with Myotonic Dystrophy Type 1

This research study is looking into a new treatment called DYNE-101 for Myotonic Dystrophy Type 1 (DM1). DM1 is a condition that causes muscle weakness and other problems. Scientists want to see if DYNE-101 can help people with DM1 and if it's safe to use. Participants will be randomly given either DYNE-101 or a placebo (a dummy treatment that looks like the real medicine but has no active ingredients). No one, not even the doctors or the patients, will know who is getting which treatment until the study ends. This helps make the results fair. The study will last for 48 weeks, and researchers will mainly look at how walking and daily tasks are affected.

De un vistazo

Estado
Autorizado
Fase
Confirmatorio terapéutico (Fase III)
Patrocinador
Dyne Therapeutics Inc.
Objetivo de inscripción
72
Inicio
28 Apr 2026

¿De qué trata este estudio?

This clinical trial is designed to investigate a new potential treatment called DYNE-101 for individuals living with Myotonic Dystrophy Type 1, often referred to as DM1. DM1 is a lifelong condition that affects muscles, causing them to weaken and not relax properly after use. It can also impact other parts of the body.

The main goal of this study is to determine if DYNE-101 can improve daily functions and overall well-being for people with DM1, while also checking if it's safe and well-tolerated. Participants will receive either DYNE-101 or a placebo, which looks identical but contains no active medicine. This method is called 'double-blind,' meaning neither the patients nor the study doctors will know who is receiving which treatment. This is a common and important way to ensure the study results are reliable and unbiased.

The study will carefully track various aspects of participants' health over 48 weeks. For example, they will measure how long it takes to complete certain walking tests, as this can indicate changes in muscle strength and function. They will also monitor side effects, changes in general health, and how the body handles the medicine. This detailed information will help researchers understand if DYNE-101 could be a valuable new option for managing DM1.

Puntos clave

  • This study is testing a new medicine (DYNE-101) for Myotonic Dystrophy Type 1.
  • It aims to see if the medicine is safe and can improve daily activities.
  • Participants will receive either the new medicine or a dummy treatment (placebo).
  • Neither you nor the doctors will know which treatment you are getting.
  • The study lasts for about 48 weeks with regular clinic visits.
  • Puedes dejar de participar en cualquier momento.

¿Quién puede ser elegible?

This study is looking for adults aged 18 years and older who have been diagnosed with Myotonic Dystrophy Type 1. Both men and women are invited to take part.

There might be other health conditions or medications that could prevent someone from joining, as these could affect the safety or results of the study. For instance, sometimes certain heart conditions, liver problems, or other serious illnesses mean a person cannot participate.

When you talk to the study team, they will go through a full list of these types of requirements to make sure the study is a safe and suitable option for you.

¿Podría este estudio ser adecuado para ti?

Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.

  1. ¿Tienes 18 años o más?
  2. Have you been diagnosed with Myotonic Dystrophy Type 1?
  3. Are you able to attend regular appointments for about a year?
  4. Are you willing to potentially receive a placebo instead of the active drug?
  5. Are you currently not taking any medications that might interfere with the study drug?
Responde cada pregunta para ver tu resultado.

¿En qué consiste la participación?

If you decide to take part, you will be in the study for about 48 weeks (just under a year). You will have regular visits to the clinic where the study team will carry out various assessments. These might include blood tests, heart checks (ECGs), checking your vital signs like blood pressure, and specific tests to measure muscle strength and how you perform daily activities, such as walking tests.

During these visits, you will receive doses of either the study medicine (DYNE-101) or the placebo. You won't know which one you are getting. The study team will explain how and when to take your medication. You will also be asked to answer questionnaires about your health and how you are feeling. All these assessments help the researchers understand the effects of the treatment. After the 48 weeks, there might be a follow-up call or visit.

Riesgos y beneficios potenciales

Taking part in this study could offer some potential benefits, such as gaining access to a new experimental treatment for Myotonic Dystrophy Type 1 that isn't yet available. You'll also receive careful monitoring of your health from a team of medical professionals. However, there's no guarantee that you will receive the active drug or that it will help your condition. There are also potential risks, including side effects from the study drug, which could range from mild to more serious. You might also experience discomfort from the tests involved, like blood draws. You have the right to withdraw from the study at any time, for any reason, without affecting your usual medical care.

Ubicaciones (7)

Algunas ubicaciones de los sitios son aproximadas. Estamos mejorando esto — por favor verifique con el equipo de prueba antes de viajar.
  • —
    No verificado
    Países Bajos
  • —
    No verificado
    España
  • —
    No verificado
    Italia
  • —
    No verificado
    Dinamarca
  • —
    No verificado
    Alemania
  • —
    No verificado
    Bélgica
  • —
    No verificado
    Francia

Preguntas comunes

What is Myotonic Dystrophy Type 1 (DM1)?

DM1 is a genetic condition that causes muscles to become weak and waste away over time. It can also affect other body systems, like the heart and digestive system.

¿Qué es un 'placebo'?

A placebo is a dummy treatment that looks exactly like the real medicine but does not contain any active ingredients. It's used to compare against the new medicine to see if it actually works better than no treatment.

What does 'double-blind' mean?

Double-blind means that neither the patient nor the doctors and study staff know whether a person is receiving the active drug or the placebo. This helps make the study fair and stops anyone's beliefs from influencing the results.

¿Cuánto tiempo estaré en el estudio?

The main part of the study will last for 48 weeks, which is just under a year. There might be some follow-up checks after that.

¿Qué tipo de pruebas tendré?

You'll have regular physical exams, blood tests, heart checks (ECGs), and tests to measure your muscle strength and ability to do daily activities, like walking.

Cómo obtener más información

Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.

Discusión

Discusión comunitaria

Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.